SCHEMBL5574232

SCHEMBL5574232

CC(C)c1ccc(S(=O)(=O)Nc2ccc(C3CCN(C(C)C)C3)nc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.43
DRD3 P35462 5/20 0.43
KCNH2 Q12809 5/20 0.43
POLB P06746 1/20 0.42
KMT2A Q03164 2/20 0.41
TRIM24 O15164 1/20 0.41
BRD1 O95696 1/20 0.41
BRPF1 P55201 1/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR6 P50406 4/20 0.40
UCHL1 P09936 1/20 0.40
USP30 Q70CQ3 1/20 0.40
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KDM4E B2RXH2 1/20 0.38
SLC2A1 P11166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1546223 0.85 DRD2 (0.46) DRD2DRD3KCNH2POLBKMT2A
Hydrochloric Acid SCHEMBL1546921 0.83 DRD2 (0.48) DRD2DRD3KCNH2POLBKMT2A
Hydrochloric Acid SCHEMBL1546919 0.83 DRD2 (0.48) DRD2DRD3KCNH2POLBKMT2A
SCHEMBL1546189 0.82 BCHE (0.48) ALDH1A1LMNASLC2A1
SCHEMBL1546730 0.81 DRD2 (0.49) DRD2DRD3KCNH2POLBKMT2A
SCHEMBL1546263 0.79 DRD2 (0.50) DRD2DRD3KCNH2POLBTRIM24
SCHEMBL1546251 0.78 DRD2 (0.44) DRD2DRD3KCNH2POLBKMT2A
SCHEMBL1546284 0.72 SLC2A1 (0.45) DRD2DRD3KCNH2POLBKMT2A
Hydrochloric Acid SCHEMBL5203406 0.72 KMT2A (0.57) DRD2DRD3KCNH2POLBKMT2A
SCHEMBL23483118 0.71 HRH3 (0.40) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814849-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2007-08-08 EP disclosed
WO-2006040182-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed